It has not been evaluated whether the present positivity is secondary to celiac disease or a characteristic of the Turkish society in the study of the frequency and clinical use of HLA antigen
in children with celiac disease in Turkey, and the percentage of this HLA antigen
is not examined in first-degree relatives and normal population.
Study of HLA antigens
in patients with osteosarcoma.
Anti-HLA antibody screen, the patient-donor HLA antigen
mismatch, hazards ratio, gender, and geographical history were compared between the two groups.
The serologic testing of HLA antigens
confirmed the presence of HLA antigens
: 3,-/w 14,- in both patients, while Rh phenotype differed minimally: in BS patient CcDee was inherited from their mother, and in his brother, BF, CCDee was inherited from their father.
The association between the HLA antigens
and Takayasu's arteritis in Thai patients.
Both class I and class II HLA antigens
are thyroid cancer susceptibility factors.
Those related to ensure the immunological compatibility include blood group compatibility; negative T and B cell complement-dependent cytotoxicity crossmatch test using donor lymphocytes as target cells; negative screening test to detect recipient reactive antibodies against HLA antigens
; and compatibility between the donor and recipient HLA genes.
in an Omani population with dilated cardiomyopathy.
The presence of anti-HLA antibodies in serum, targeting donor HLA antigens
, induces donor cells complement-dependent cytotoxicity.
Sensitization to human leukocyte antigens (HLA) in transplant immunology is the occurrence of alloantibodies in the serum of patients who desire to receive organs, directed towards HLA antigens
. Sensitization in transplant candidates is normally associated to one or more risk factors such as previous transfusions, pregnancy or transplants (VONGWIWATANA et al., 2003; SOOSAY et al., 2003; MAO et al., 2007).
in Turkish race with rheumatic heart disease.
T cells were phenotyped for HLA-class I alleles (A and B), while B cells were employed in the phenotyping of HLA-class II alleles (DR and DQ) in the microlymphocytotoxicity test, (11) using a panel of monoclonal antibodies (Biotest Company, Germany) that were able to recognize 8 A, 20 B, 10 DR, and 4 DQ HLA antigens
There are some disadvantages in MLCT like requirement of viable cells, cross-reactive nature of HLA antigens
, unavailability of B* 27 specific antisera which cover all HLA-B* 27 alleles and the need for expert to give consistent cytotoxic results .
This technology uses microbeads coated with class I or class II HLA antigens
and a fluorescence flow analyzer.
The antibodies were directed against the HLA antigens
of the actually and previously failed grafts, but there was also unspecific activity present.